Brainsway Ltd. (BWAY)
| Market Cap | 136.68M |
| Revenue (ttm) | 22.06M |
| Net Income (ttm) | -5.39M |
| Shares Out | 16.45M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,801 |
| Open | 7.71 |
| Previous Close | 7.78 |
| Day's Range | 7.57 - 8.12 |
| 52-Week Range | 5.55 - 11.77 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 11.19 (+39.8%) |
| Est. Earnings Date | Nov 17, 2021 |
About BWAY
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains t...
Financial Performance
In 2020, Brainsway's revenue was $22.06 million, a decrease of -4.52% compared to the previous year's $23.10 million. Losses were -$5.39 million, -47.86% less than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Brainsway stock is "Strong Buy." The 12-month stock price forecast is 11.19, which is an increase of 39.84% from the latest price.
News
BrainsWay to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...
BrainsWay Stock Gains On FDA Expanded Use Approval For Its Stimulation Device
The FDA has cleared BrainsWay Ltd's (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious de...
FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients
Expanded Depression Indication Further Demonstrates Company's Leadership Position Expanded Depression Indication Further Demonstrates Company's Leadership Position
BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders
BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...
BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights
Strong Revenue Growth of 45% Year-over-Year in Q2 2021
BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021
CRESSKILL, N.J. and JERUSALEM, July 28, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments ...
MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive...
Engaging event for local mental health clinicians to learn more about BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) helmet, cleared to treat MDD and OCD, currently available in Charlotte.
BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate
CRESSKILL, N.J. and JERUSALEM, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation tr...
BrainsWay (BWAY) is in Overbought Territory: What's Next?
BrainsWay (BWAY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Brainsway Ltd. Sponsored ADR (BWAY) Moves 10.6% Higher: Will This Strength Last?
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average.
BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™
CRESSKILL, N.J. and JERUSALEM, May 24, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments f...
BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights
Strong Revenue Growth of 47% Year-over-Year in Q1 2021
BrainsWay to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit
CRESSKILL, N.J. and JERUSALEM, May 19, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disord...
Should You Buy BrainsWay (BWAY) Ahead of Earnings?
BrainsWay (BWAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BrainsWay to Report First Quarter 2021 Financial Results on May 20, 2021
CRESSKILL, N.J. and JERUSALEM, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brai...
BrainsWay Announces Appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer
CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments f...
BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month
The Sweepstakes, demonstrating how Deep Transcranial Magnetic Stimulation (Deep TMS) can fit into an average day, offers participants a chance to be one of 20 winners who will receive a curated self-car...
BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers
Patients in areas across the country now have access to Deep Transcranial Magnetic Stimulation (Deep TMS) therapy as an aid for short-term smoking cessation Patients in areas across the country now have...
Strength Seen in Brainsway Ltd. Sponsored ADR (BWAY): Can Its 7.3% Jump Turn into More Strength?
Brainsway Ltd. Sponsored ADR (BWAY) witnessed a jump in share price last session on above-average trading volume.
BrainsWay Stock Is Trading Higher After FDA OK's Three-Minute Theta Burst Treatment Protocol For Major Depressive Dis...
The FDA has granted 501(k) clearance for BrainsWay Ltd's (NASDAQ: BWAY) Theta Burst three-minute protocol utilizing its Deep Transcranial Magnetic Stimulation (Deep TMS) system for major depressive diso...
BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder
Shorter Protocol Further Expands Access to Care Shorter Protocol Further Expands Access to Care
BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS)
The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction
BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights
Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET
BrainsWay to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021
CRESSKILL, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today a...